Costs

How much does stem cell therapy for Scleroderma (Systemic Sclerosis) cost? (2026)

The comparison dataset stores a Bulgaria planning observation of €3,000–€8,000 for treatment, compiled from cited public commercial sources. It is not a quotation from Stem Plus, and different products, doses, visits and inclusions must not be treated as equivalent. The stored registry query contains 44 Scleroderma (Systemic Sclerosis) records. Registration does not mean that a study is recruiting, that a person is eligible, or that treatment and travel are free; verify the current record and sponsor-cost terms directly.

Medical review statusPending clinical sign-offLast evidence update: 2026-08-05Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

Systemic sclerosis (scleroderma) is an autoimmune disease involving fibrosis and vascular and immune dysfunction that may affect skin and internal organs. Two very different approaches must not be conflated. Autologous haematopoietic stem-cell transplantation (HSCT) is an intensive specialist treatment considered in selected people with severe, early diffuse cutaneous systemic sclerosis after careful cardiopulmonary risk assessment. Placental or other mesenchymal stromal cell (MSC) products remain investigational and have not established the same clinical role. The registry table on this page lists relevant studies and their current recruitment status.

What drives the cost for Scleroderma (Systemic Sclerosis)

Costs for specialist autologous HSCT and investigational MSC infusion are not comparable. HSCT involves mobilisation, conditioning chemotherapy, hospital care and prolonged monitoring; an MSC infusion is a different experimental product and procedure. Private quotations may exclude pre-treatment organ assessment, standard systemic-sclerosis care, travel and management of complications. Patients should obtain an itemised written quote and written confirmation of sponsor, insurer and patient responsibilities without treating price as evidence of benefit.

Randomised evidence and specialist recommendations support considering autologous HSCT for carefully selected severe early diffuse disease, while recognising substantial treatment-related risk. That evidence cannot be transferred to placental MSC infusion: the products, conditioning, mechanism, risks and endpoints are fundamentally different. MSC studies remain early and heterogeneous. No combined response rate is published here. The registered studies and their own prespecified endpoints are listed in the registry table on this page.

Indicative published cost observations for Scleroderma (Systemic Sclerosis): roughly €20,000–€27,500 across the cited provider and aggregator pages (source register: dvcstem.com). Protocols, inclusions and jurisdictions differ, so these figures are not automatically comparable quotations.

Scleroderma (Systemic Sclerosis) cost by country — comparison (2026)

LocationIndicative treatment costRegulation
Bulgaria (EU) · e.g. Stem Plus€3,000–€8,000Verify provider and laboratory certificates
USA€4,600–€46,000Non-EU; verify provider and product status
UK€4,880–€49,000Non-EU; verify provider and product status
Germany€11,000–€36,700EU member state; verify provider and product status
Switzerland€20,000–€40,000Non-EU; verify provider and product status
Mexico€3,000–€12,000Non-EU; verify provider and product status
India€3,000–€8,000Non-EU; verify provider and product status
Serbia€7,000–€31,000Non-EU; verify provider and product status
Turkey€6,000–€18,000Non-EU; verify provider and product status
Thailand€8,000–€20,000Non-EU; verify provider and product status
Panama€15,000–€27,000Non-EU; verify provider and product status
Indicative Scleroderma (Systemic Sclerosis) programme cost by country (EUR, treatment only)
Bulgaria (published range)€5,500
India€5,500
Mexico€7,500
Turkey€12,000
Thailand€14,000
Serbia€19,000
Panama€21,000
Germany€23,850
USA€25,300
UK€26,940
Switzerland€30,000
Want your real all-in cost including flights and hotel from your city? Use the cost calculator — you set every number.

Price varies with cell type, dose, number of sessions, diagnostics, supportive care and follow-up. A lower range does not establish equivalent quality or outcome. Request a fixed written quote and verify the therapy and provider with the relevant authorities. Check registered trials before paying privately.

Scleroderma (Systemic Sclerosis) cost — common questions

Why is Scleroderma (Systemic Sclerosis) stem-cell treatment so much cheaper in Bulgaria?

The collected commercial ranges differ, but they may describe different products, doses, visits and inclusions. A lower quote does not establish equivalent quality, evidence or regulatory status.

Is a cheaper programme riskier?

Price alone cannot establish risk. Verify the exact treatment status, provider and manufacturing authorisations, product identity, release testing, adverse-event plan and primary evidence.

Does the price include travel and hotel?

The €3,000–€8,000 range covers the medical programme. Add flights, hotel and recovery with our calculator for your true all-in cost from your city.

Will I get a fixed quote, or an open-ended bill?

Ask for a written quotation after clinical review, with the exact product, inclusions, exclusions, cancellation terms and circumstances in which charges may change. A website estimate is not a binding quote.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

Indicative ranges for planning, compiled from public market data; confirmed pricing follows a medical review. Not medical advice.

Explore all sections · Data & downloads

Compare cell-therapy evidence, registered studies and published price observations.

StemCellAtlas is a source-first research and cost-planning guide. It separates registry and regulator evidence from heterogeneous commercial observations.

Request written information